Tildrakizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Interleukin 23 (IL23) |
| Clinical data | |
| Trade names | Ilumya |
| Other names | Tildrakizumab-asmn |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618026 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6426H9918N1698O2000S46 |
| Molar mass | 144436.68 g·mol−1 |
Tildrakizumab, sold under the brand name Ilumya among others, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[4] It is approved for the treatment of adults with moderate-to-severe plaque psoriasis in the United States and in the European Union.[2][3][5]
Tildrakizumab was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.[6][7]
- ^ "Summary Basis of Decision (SBD) for Ilumya". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b "Ilumya- tildrakizumab-asmn injection, solution". DailyMed. 11 April 2024. Retrieved 2 July 2024.
- ^ a b "Ilumetri EPAR". European Medicines Agency. 17 September 2018. Retrieved 2 July 2024.
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council—Tildrakizumab", American Medical Association.
- ^ "FDA approves Ilumya for plaque psoriasis". National Psoriasis Foundation. 22 March 2018.
- ^ Dolgin E (December 2016). "New anti-IL-23 drugs raise hopes for psoriasis plaque clearance". Nature Biotechnology. 34 (12): 1218–1219. doi:10.1038/nbt1216-1218. PMID 27926724. S2CID 205273437.
- ^ Galluzzo M, D'adamio S, Bianchi L, Talamonti M (May 2017). "Tildrakizumab for treating psoriasis". Expert Opinion on Biological Therapy. 17 (5): 645–657. doi:10.1080/14712598.2017.1304537. PMID 28271735. S2CID 4041245.